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Abstract: Antibiotic resistance is a major cause of the increasing failures in the current eradication
therapies against Helicobacter pylori. In this scenario, repurposing drugs could be a valuable strategy
to fast-track novel antimicrobial agents. In the present study, we analyzed the inhibitory capability
of 1,4-dihydropyridine (DHP) antihypertensive drugs on the essential function of the H. pylori
response regulator HsrA and investigated both the in vitro antimicrobial activities and the in vivo
efficacy of DHP treatments against H. pylori. Six different commercially available and highly
prescribed DHP drugs—namely, Nifedipine, Nicardipine, Nisoldipine, Nimodipine, Nitrendipine,
and Lercanidipine—noticeably inhibited the DNA binding activity of HsrA and exhibited potent
bactericidal activities against both metronidazole- and clarithromycin-resistant strains of H. pylori,
with minimal inhibitory concentration (MIC) values in the range of 4 to 32 mg/L. The dynamics of the
decline in the bacterial counts at 2 × MIC appeared to be correlated with the lipophilicity of the drugs,
suggesting different translocation efficiencies of DHPs across the bacterial membrane. Oral treatments
with 100 mg/kg/day of marketed formulations of Nimodipine or Nitrendipine in combination with
omeprazole significantly reduced the H. pylori gastric colonization in mice. The results presented
here support a novel therapeutic solution for treatment of antibiotic-resistant H. pylori infections.
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1. Introduction
Helicobacter pylori is a microaerophilic Gram-negative bacterium that currently colonizes the
gastric epithelium of almost 4.4 billion people worldwide [1]. Unless treated, infection of human
stomach usually persists lifelong, causing gastric inflammation and contributing to the pathogenesis
of peptic ulcer disease, gastric adenocarcinoma, and mucosa-associated lymphoid-tissue (MALT)
lymphoma [2,3]. H. pylori has been classified as a class I human carcinogen by the International Agency
for Research of Cancer. In fact, near 90% of non-cardia gastric cancer worldwide and approximately
5% of the total burden from all cancers globally can be attributable to H. pylori infection [4].
The increasing prevalence of antibiotic-resistant strains of H pylori, the high rates of
antibiotic-associated side effects and the low patient compliance have led to a significant reduction in
the eradication rates of traditional standard triple therapies, which are based on the co-administration
of a proton pump inhibitor (PPI) and two antibiotics, clarithromycin and either amoxicillin or
metronidazole for 7 to 10 days. To face this emerging health issue, the current guidelines recommend a
quadruple therapy (PPI + amoxicillin + metronidazole + clarithromycin) administered for 14 days
as first-line strategy in adults, while the PPI triple therapy has been restricted to areas with known
low clarithromycin resistance [5]. Further, in February 2017 the World Health Organization included
H. pylori in its first ever list of antibiotic-resistant “priority pathogens”, a catalogue of 12 families of
bacteria that pose at present the greatest threat to human health [6]. Nowadays, an effective novel
therapy against H. pylori is mandatory in order to overcome the current resistome and minimize side
effects on normal microbiota.
One of the major causes of the present antibiotic resistance crisis is the lack of development of
new antimicrobial drugs by the pharmaceutical industry due to reduced economic incentives and
challenging regulatory requirements. Since any new antibiotic is reserved in clinical practice for only
the worst cases of illness due to the fear of promoting drug resistance, its reduced use and relatively
low cost for the patient represent a diminished return on investment [7,8]. Drug repurposing has
emerged as an alternative approach for the development of novel and effective antimicrobial therapies.
This strategy, consisting in discovering a novel clinical use for an existing drug previously approved for
a different therapeutic indication, can minimize the costs and risks associated with drug development
programs and accelerate the delivery of new therapeutics to patients with refractory infections or
emerging infectious diseases [9,10]. Hence, the search for drug repurposing candidates able to inhibit
the growth of pathogens by acting specifically on new molecular targets can be a valuable route for
drug discovery.
In H. pylori, the essential response regulator HsrA appears to be a promising target for drug
development [11–16]. HsrA (for homeostatic stress regulator) is unique among members of the
Epsilonproteobacteria [12] and functions as a global transcriptional regulator, synchronizing metabolic
functions and virulence with the availability of nutrients and cell division [13], mediating also
the response to oxidative stress [14]. Attempts at both deletion and overexpression of HsrA have
been unsuccessful, supporting not only an essential function of the regulator but also a very tight
post-transcriptional control of its expression that ensures appropriate levels of the protein into the
cell [12,15]. In a previous study, we screened the Prestwick Chemical Library®, a collection of 1120
FDA-approved, off-patent small molecules for identifying compounds that specifically bind to HsrA and
potentially inhibit its essential function. At least 14 compounds (1.25%) of the Prestwick repurposing
library bound to the native state of HsrA and notably increased the protein conformational stability
against thermal denaturation, causing a shift of the protein unfolding curve to higher temperatures due
to the increased melting temperature (Tm) of the protein–compound complexes [17]. Despite most of the
identified HsrA binders from the Prestwick library consisting of naturally occurring flavonoids, several
other FDA-approved drugs formed stable complexes with HsrA and enhanced its thermodynamic
stability, including the 1,4-dihydropyridine (DHP) calcium channel blocker Nicardipine [18,19]. In the
present study, we investigated the effect of Nicardipine and other commercially available DHP
derivative drugs on the biological activity of the H. pylori essential response regulator HsrA and
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characterized the molecular interaction between these drugs and the target protein. Bactericidal
activities of selected DHP-class inhibitors of HsrA as well as their potential synergistic effects in
combination with conventional antibiotics used as first-line treatment against H. pylori infection
(metronidazole and clarithromycin) were also evaluated. In addition, the efficacy of two representative
DHP drugs in eradicating the H. pylori gastric mucosal colonization was assessed in a mouse model.
2. Materials and Methods
2.1. Chemicals
DHP drugs for in vitro experiments were purchased from Sigma-Aldrich (Saint Louis, MO, USA)
and properly stored according to the manufacturer’s instructions. Stock solutions of each drug were
freshly prepared at 20 mM in 100% dimethyl sulfoxide (DMSO) for electrophoretic mobility shift
assays and isothermal titration calorimetry analyses, and at 10.24 g/L in 100% DMSO for minimal
inhibitory concentration (MIC)/minimal bactericidal concentration (MBC) determinations. Since DHPs
are light-sensitive compounds, all stock solutions were protected from light. Metronidazole and
clarithromycin were obtained from Sigma-Aldrich. Stock solutions of these antibiotics in 100% DMSO
were prepared at 10.24 g/L and stored at −20 ◦C for up to 30 days. Marketed formulations (oral tablets)
of DHP drugs for in vivo efficacy studies were purchased from STADA S.L. (Bad Vilbel, Germany).
2.2. Bacterial Strains, Culture Media and Growth Conditions
H. pylori reference strains ATCC 700392, ATCC 43504 (metronidazole-resistant), and ATCC 700684
(clarithromycin resistant) were purchased from the American Type Culture Collection and used in the
in vitro antibacterial assays. The strains were grown in Blood Agar Base No.2 (OXOID) supplemented
with 8% defibrinated horse blood (OXOID) in a humidified microaerobic incubator (85% N2, 10% CO2,
5% O2) at 37 ◦C for 48–72 h. For certain experiments, bacteria were grown for 48–72 h at 37 ◦C in
brain heart infusion broth (OXOID) supplemented with 4% fetal bovine serum (Gibco). For in vivo
experiments, the CagA+ mouse colonizing strain pre-mouse Sydney Strain 1 (PMSS1) [20,21], obtained
from the French National Reference Center for Campylobacters & Helicobacters (www.cnrch.fr), was
used. For infection inocula, H. pylori PMSS1 was grown on in-house selective Wilkins Chalgren agar
plates [22] under microaerobic conditions and transferred to Brucella broth medium as described below.
2.3. Electrophoretic Mobility Shift Assays
The in vitro biological activity of the H. pylori HsrA response regulator and its potential inhibition
by DHP drugs were assessed by electrophoretic mobility shift assay (EMSA) as previously described [17].
Briefly, 120 ng of target DNA (promoter region of the H. pylori porGDAB operon [14]) was mixed with 6
µM of recombinant HsrA [17] in the presence of increasing concentrations (0.1 to 2 mM) of selected
DHP drugs. Mixtures of DNA and protein in a 20 µL reaction volume containing 10 mM bis-Tris (pH
7.5), 40 mM KCl, 100 mg/L BSA, 1 mM DTT and 5% glycerol were incubated at room temperature for
20 min and then separated by 6% native polyacrylamide gel electrophoresis. A 150 bp fragment of
the Anabaena sp. PCC 7120 gene pkn22 was included as non-specific competitor DNA in all assays.
EMSA gels were stained with SYBR Safe® (Thermo Fisher Scientific, Bothell, WA, USA) and analyzed
using the Bio-Rad Gel Doc 2000 imaging system.
2.4. Minimal Inhibitory and Bactericidal Concentrations
MIC determinations were carried out by the broth microdilution method as previously
described [17,23,24]. Briefly, H. pylori strains were grown for 48 h at 37 ◦C under microaerobic
conditions (85% N2, 10% CO2, 5% O2) in brain heart infusion broth supplemented with 4% fetal bovine
serum (BHI+FBS). Fresh inoculums at ~106 CFU/mL were prepared by dilution of the bacterial cultures
in the same BHI+FBS medium to a final optical density at 600 nm of 0.01. DHP drugs were serially
two-fold diluted in the bacterial inoculum from 256 to 0.125 mg/L using sterile 96-well flat-bottom
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microtiter plates and then incubated under microaerobic conditions at 37 ◦C for 72 h. For MBC
determinations, 10 µL aliquots of two dilutions around the MIC value were plated on inhibitor-free
Blood Agar Base No.2 with 8% defibrinated horse blood and incubated for 72 h. Each experiment was
performed twice in triplicate
2.5. Time–kill Kinetics Assays
Time–kill curves for selected DHP drugs were determined using the H. pylori strain ATCC
700684 [17]. A bacterial suspension of 5.0 × 105 CFU/mL was freshly prepared in BHI+FBS and mixed
with each DHP at a final concentration of 2-fold the corresponding MIC value. DMSO instead of drugs
was included as control. Colony forming units (CFUs) were determined after 4, 8, and 24 h of drug
exposition by culturing on Blood Agar Base No.2 supplemented with 8% defibrinated horse blood for
72 h under microaerobic conditions. Each determination was performed twice in triplicate and the
results were presented as log10 CFU/mL versus incubation time. Statistical analysis was performed
using the Mann–Whitney U test. A p value smaller than 0.05 was considered significant.
2.6. Checkerboard Assays
Antibacterial synergies of selected DHPs in combination with first-line anti-H. pylori antibiotics
were tested by the checkerboard assay [17]. Using 96-well flat-bottom microtiter plates, we assayed the
antibacterial effect of the interaction of a range of 2-fold dilutions of clarithromycin or metronidazole
with a range of 2-fold dilutions of each selected DHP. Serial dilutions of both antimicrobials (antibiotic
and DHP) were firstly prepared using two different sterile microtiter plates, one compound was diluted
along the rows in a first plate, and the other compound was diluted along the columns of a second plate.
Then, both gradients were mixed in a third microtiter plate and inoculated with a freshly prepared
bacterial suspension of H. pylori at 2 × 106 CFU/mL in BHI+FBS. Plates were incubated for 48 h at
37 ◦C under microaerobic conditions. After this time, microbial growth was colorimetric revealed by
addition of 0.01 mg/mL resazurin (Sigma-Aldrich). The interaction between drugs was determined
by calculating the fractional inhibitory concentration index (FICI) as: FICA (MICA in the presence of
B/MICA alone) + FICB (MICB in the presence of A/MICB alone) [25].
2.7. Isothermal Titration Calorimetry Assays
Thermodynamic parameters of the molecular interaction between HsrA and its DHP-class
inhibitors were analyzed by isothermal titration calorimetry (ITC) using an AutoiTC200 calorimeter
(MicroCal, Malvern Instruments, Malvern, Worcestershire, UK). A solution of 20 µM of the protein
in 50 mM Tris-HCl [pH 8], 150 mM NaCl, 10% glycerol, 1% DMSO was titrated with 200 µM of the
corresponding ligand (DHP) dissolved in the same buffer at 25 ◦C. A total of 19 injections of 2 µL was
added sequentially to the sample cell after 150 s spacing to ensure that the thermal power returned
to the baseline before the next injection [26]. Dissociation constants and binding enthalpies were
calculated by non-linear least squares regression data analysis using the software package Origin 7.0
(OriginLab, Northampton, MA, USA).
2.8. Molecular Docking
Molecular docking analyses were performed using the program AutoDock Vina 1.1.2 [27] in
order to estimate the conformation of the HsrA-DHP complexes. The chemical structures of ligands
(Nifedipine, Nicardipine, Nisoldipine, Nimodipine, Nitrendipine, and Lercanidipine) were retrieved
from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/). The structure of the H. pylori
HsrA response regulator (2HQR, model 1, chain A) was downloaded from the Protein Data Bank
(https://www.rcsb.org/). The protein and the ligands were prepared using the AutoDock Tools program.
Rotatable bonds were defined as free for the ligands and rigid for the protein. The AutoGrid algorithm
was used to estimate the interaction energy of each ligand pose. The pose that exhibited the lowest free
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energy of interaction (∆G, kcal/mol) for each ligand was considered as its predicted model of binding
to the target protein.
2.9. Mouse Infection and DHP Treatment
The in vivo evaluation of anti-Helicobacter pylori activity of selected DHPs was carried out in
the C57BL/6 mouse model [20]. The experiments were performed in specific pathogen-free animal
facilities at the University of Bordeaux (France). The study was approved by a local ethical committee
of the University of Bordeaux and conforms to the French Ministry of Agriculture Guidelines on
Animal Care and the French Committee of Genetic Engineering, with respect to the principle of the 3Rs
(Replacement, Reduction and Refinement; approval number 201812051729186–V6 APAFiS #17999).
Six-week-old specific pathogen-free C57BL/6 female mice (n = 38) were purchased from Charles
River Laboratories (Saint-Germain-Nuelles, France). Animals were housed in polycarbonate cages
and acclimatized for one week before starting the experiments. Two groups of 9 mice were fasted
to facilitate bacterial colonization and then force-fed for 3 consecutive days with a dose of 108 CFU
in 100 µL of H. pylori strain PMSS1 [21,28]. Bacterial inocula were freshly prepared in Brucella broth
medium from cultures grown on in-house Wilkins Chalgren agar plates supplemented with 10%
human blood and 10 µg/mL of vancomycin, 5 µg/mL of trimethoprim, 1 µg/mL of amphotericin B and
2 µg/mL of cefsulodin [22] under microaerobic conditions (85% N2, 10% CO2, 5% O2) at 35 ◦C for 48 h.
Four weeks after inoculation, all mice of each group were treated orally with 100 mg/kg/day of
marketed formulations (oral tablets, STADA S.L., Bad Vilbel, Germany) of Nimodipine or Nitrendipine
in combination with omeprazole (140 mg/kg/day) daily, for 7 days. Two additional groups of 10 mice
were used as controls, one non-infected and one H. pylori-infected non-treated group. Both control
groups received omeprazole (140 mg/kg/day) for the 7 days of treatments.
All the animals were sacrificed by cervical dislocation one month after the end of treatments.
The stomach of each mouse was properly isolated, opened by the large curvature using a small curved
chisel, and put in a petri dish with saline buffer to remove the food inside. The organs were cut along
the axis of the large curvature, and then cut along the axis of the small curvature. A fragment of the
right half-stomach cleared of the cardia was introduced into an RNase/DNase free tube containing
200 µL of sterile saline buffer for bacteriological cultures and molecular studies.
2.10. Bacterial Counts and qPCR
Quantitative cultures to determine the bacterial load in gastric biopsies were carried out as follows.
Stomach fragments from each mouse were harvested as described above and weighed. Then, the
stomach fragments were crushed using a sterile pestle and serial dilutions of the homogenized organs
were spread on Wilkins Chalgren agar plates supplemented with 10% human blood and 10 µg/mL
of vancomycin, 5 µg/mL of trimethoprim, 1 µg/mL of amphotericin B and 2 µg/mL of cefsulodin.
Plates were incubated under microaerobic conditions (85% N2, 10% CO2, 5% O2) at 35 ◦C and colonies
were counted after at least 5 days of incubation. H. pylori was identified by its phenotypic and
biochemical characteristics (morphology, urease test, oxidase test). Colony counting was performed by
two independent experiments and the results were expressed as CFU/mg of stomach.
The efficacy of the DHP treatments to eradicate H. pylori stomach colonization in the mouse model
was also determined by quantitative PCR. DNA was extracted from each homogenized stomach using
the Arrow system (Nordiag, Bergen, Norway). A quantitative PCR using Fluorescence Resonance
Energy Transfer (FRET) technology targeting DNA coding for H. pylori 23S ribosomal RNA (rRNA)
was performed. Primers described by Oleastro and co-workers [29] were used to amplify the 23S rRNA
gene and primers described by Laur and co-workers [30] were used to amplify the glyceraldehyde
3-phosphate dehydrogenase (GAPDH) gene. Each target was tested in duplicate on all samples.
A standard curve was prepared using serial dilutions of a DNA extract from a CFU/mL calibrated
bacterial suspension of the H. pylori PMSS1 strain. The LightCycler® 480 SYBR® Green I Master
Mix (Roche Diagnostics, Rotkreuz, Switzerland), compatible with the LightCycler® 480 thermocycler
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(Roche Diagnostics), was used according to the manufacturer’s instructions. The SYBR® Premix Ex
Taq™ Mix (Tli RNaseH Plus) (Takara Bio Inc., Shiga, Japan) compatible with the PCR thermocycler
CFX96™ (Bio-Rad Laboratories, Hercules, CA, USA) available at the TBMCore real-time PCR platform
(University of Bordeaux, France) was used according to the manufacturer’s instructions. The PCR
started with a 95 ◦C DNA denaturation step for 3 min, followed by 40 cycles comprising two steps:
a 95 ◦C denaturation step for 5 s and a 60 ◦C primer hybridization step for 30 s. After each cycle,
fluorescence was measured in order to quantify newly synthesized DNA. At the end of the procedure, a
melting curve was generated by a slow elevation in the temperature from 65 to 95 ◦C and the continuous
measurement of fluorescence. The generation of this melting curve permitted the verification of one
specific peak at the expected melting temperature for each product, which showed the PCR specificity.
The final results were expressed as a ratio of bacteria/murine cells. DNA extracted from the m-ICcl2
murine epithelial cell line available in the laboratory was used to express the results as a ratio of
bacteria/murine cells. The detection limit of this method was around 0.001 bacteria/murine cell for H.
pylori, as previously described [28].
2.11. Statistical Analysis
Bacterial counts (CFU/mg) and qPCR results (Helicobacter/10,000 murine cells) were compared
between each DHP-treated group and the infected non-treated control group. Statistical analyses were
carried out using the non-parametric Mann–Whitney test. A p value smaller than 0.05 was considered
significant. All statistics were performed using GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla,
CA, USA).
3. Results
3.1. DHPs Inhibit the DNA Binding Activity of the H. pylori Essential Response Regulator HsrA
Previous high-throughput screening of the Prestwick Chemical Library® using a fluorescence
-based thermal shift assay identified Nicardipine (Cardene) as a specific HsrA binder that preferentially
bound to the native state of the H. pylori essential response regulator and increased the protein
conformational stability, causing a shift of the protein unfolding curve to higher temperatures [17].
Since Nicardipine shares a similar chemical structure with other DHP-class calcium channel blockers,
we investigated the effect of Nicardipine and other five commercially available DHP derivative drugs
(Table 1) on the in vitro biological activity of HsrA.
HsrA functions as a transcriptional activator of gene expression; hence, it interacts with DNA
and binds to specific sequences located in target promoters, thereby modulating gene expression.
EMSA analyses of HsrA in the presence of its target promoter PporGDAB demonstrated a high affinity of
HsrA by its target DNA in a concentration-dependent manner (Figure 1a). Under the experimental
conditions used in EMSAs, 120 ng of target DNA were completely and specifically complexed to HsrA
from 6 µM of the recombinant protein. Hence, this concentration was subsequently used for EMSA
inhibition assays in the presence of 100 µM to 2 mM of each DHPs. As shown in Figure 1b, all the
DHPs tested notably inhibited the in vitro DNA binding activity of HsrA to its target promoter. No
relevant differences were observed in the inhibitory capacities of Nifedipine, Nicardipine, Nisoldipine,
Nimodipine, Nitrendipine and Lercanidipine on the HsrA biological activity according to EMSAs.
In all cases, 1 mM of DHP was sufficient to completely inhibit the in vitro biological activity of 6 µM of
recombinant HsrA protein. In the cases of Nicardipine, Nisoldipine and Nifedipine, the activity of the
regulator was partially inhibited even at 100 µM of these drugs under the experimental conditions
used in our binding assays.
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Table 1. The 1,4-dihydropyridine (DHP) derivative drugs tested in this work as novel antimicrobials
against Helicobacter pylori infection.
Drug
(Brand Name)
DHP
Generation
Molecular
Formula Chemical Structure
Mouse LD50
(mg/kg, oral) *
Nifedipine
(Adalat) first C17H18N2O6
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of 6 µM of recombinant HsrA protein. In the cases of Nicardipine, Nisoldipine and Nifedipine, the 
activity of the regulator was partially inhibited even at 100 µM of these drugs under the experimental 
conditions used in our binding assays.  
411
Nimodipine
(Nimotop) second C21H26N2O7
Phar aceutics 2020, 12, x F R PEER REVIE  7 of 18 
 
isoldip ne 
(Sular) 
second 20 4 2 6 
 
411 
i odipine 
( i ot p) 
second 21 26 2 7 
 
940 
itrendipine 
(Baypress) 
third 18 20 2 6 
 
2540 
Lercanidipine 
(Zanidip) 
fourth 36 41 3 6 622 
* edian lethal dose (L 50) data fro  Pub he . Lercanidipine L 50 infor ation fro  [31]. 
sr  functions as a transcriptional activator of gene expression; hence, it interacts ith  
and binds to specific sequences located in target pro oters, thereby odulating gene expression. 
E S  analyses of sr  in the presence of its target pro oter PporGDAB de onstrated a high affinity of 
sr  by its target  in a concentration-dependent anner (Figure 1a). nder the experi ental 
conditions used in E S s, 120 ng of target  ere co pletely and specifically co plexed to 
sr  fro  6  of the reco binant protein. ence, this concentration as subsequently used for 
E S  inhibition assays in the presence of 100  to 2  of each Ps. s sho n in Figure 1b, all 
the Ps tested notably inhibited the in vitro  binding activity of sr  to its target pro oter. 
o relevant differences ere observed in the inhibitory capacities of ifedipine, icardipine, 
isoldipine, i odipine, itrendipine and Lercanidipine on the sr  biological activity according 
to E S s. In all cases, 1  of P as sufficient to co pletely inhibit the in vitro biological activity 
of 6  of reco binant sr  protein. In the cases of icardipine, isoldipine and ifedipine, the 
activity of the regulator as partially inhibited even at 100  of these drugs under the experi ental 
conditions used in our binding assays.  
940
Nitrendipine
(Baypress) third C18H20N2O6
Pharmaceutics 2020, 12, x FOR PEER REVIEW 7 of 18 
 
Nisoldipine 
(Sular) 
second C20H24N2O6 
 
411 
Nimodipine 
(Nimotop) 
second C21H 6N2O7 
 
940 
Nitrendipine 
(Baypress) 
third C18H20N2O6 
 
2540 
Lercanidipine 
(Zanidip) 
fourth C36H41N3O6 622 
* Median lethal dose (LD50) data from PubChem. Lercanidipine LD50 information from [31]. 
HsrA functions as a transcriptional activator of gene expression; hence, it interacts with DNA 
and binds to specific sequences located in target promoters, thereby modulating gene expression. 
EMSA analyses of HsrA in the presence of its target promoter PporGDAB demonstrated a high affinity of 
HsrA by its target DNA in a concentration-dependent manner (Figure 1a). Under the experimental 
conditions used in EMSAs, 120 ng of target DNA were completely and specifically complexed to 
HsrA from 6 µM of the recombinant protein. Hence, this concentration was subsequently used for 
EMSA inhibition assays in the presence of 100 µM to 2 mM of each DHPs. As shown in Figure 1b, all 
the DHPs tested notably inhibited the in vitro DNA binding activity of HsrA to its target promoter. 
No relevant differences were observed in the inhibitory capacities of Nifedipine, Nicardipine, 
Nisoldipine, Nimodipine, Nitrendipine and Lercanidipine on the HsrA biological activity according 
to EMSAs. In all cases, 1 mM of DHP was sufficient to completely inhibit the in vitro biological activity 
of 6 µM of recombinant HsrA protein. In the cases of Nicardipine, Nisoldipine and Nifedipine, the 
activity of the regulator was partially inhibited even at 100 µM of these drugs under the experimental 
conditions used in our binding assays.  
2540
Lercanidipine
(Zanidip) fourth C36H41N3O6
Pharmaceutics 2020, 12, x FOR PEER REVIEW 7 of 18 
 
Nisoldipine 
(Sular) 
second C20H24N2O6 
 
411 
Nimodipine 
(Nimotop) 
second C21H26N2O7 
 
940 
Nitrendipine 
(Baypress) 
third C18 20  
 
2540 
Lercanidipine 
(Zan dip) 
fourth C36 41 3 6 622 
* Median lethal dose (LD50) data from PubChem. Lercanidipine LD50 information from [31]. 
HsrA functions as a transcriptional activator of gene expression; hence, it interacts with DNA 
and binds to specific sequences located in target promoters, thereby modulating gene expression. 
EMSA analyses of HsrA in the presence of its target promoter PporGDAB demonstrated a high affinity of 
HsrA by its target DNA in a concentration-dependent manner (Figure 1a). Under the experimental 
conditions used in EMSAs, 120 ng of target DNA were completely and specifically complexed to 
HsrA from 6 µM of the recombinant protein. Hence, this concentration was subsequently used for 
EMSA inhibition assays in the presence of 100 µM to 2 mM of each DHPs. As shown in Figure 1b, all 
the DHPs tested notably inhibited the in vitro DNA binding activity of HsrA to its target promoter. 
No relevant differences were observed in the inhibitory capacities of Nifedipine, Nicardipine, 
Nisoldipine, Nimodipine, Nitrendipine and Lercanidipine on the HsrA biological activity according 
to EMSAs. In all cases, 1 mM of DHP was sufficient to completely inhibit the in vitro biological activity 
of 6 µM of recombinant HsrA protein. In the cases of Nicardipine, Nisoldipine and Nifedipine, the 
activity of the regulator was partially inhibited even at 100 µM of these drugs under the experimental 
conditions used in our binding assays.  
622
* Median lethal dose (LD50) data from PubChem. Lercanidipine LD50 information from [31].
Pharmaceutics 2019, 11, 681 8 of 18
Pharmaceutics 2020, 12, x FOR PEER REVIEW 8 of 18 
 
 
Figure 1. In vitro inhibition of HsrA DNA binding activity by selected DHP drugs. (a) Electrophoretic 
mobility shift assays (EMSAs) showing the ability of recombinant HsrA to specifically bind the 
promoter region of target porGDAB operon. Increasing concentrations of HsrA (indicated in µM) were 
mixed with 120 ng of target promoter and separated on a 6% PAGE. The Anabaena gene pkn22 was 
included as non-specific competitor DNA in all assays. (b) DNA fragments were mixed with 6 µM of 
recombinant HsrA protein in the presence of 2, 1, 0.5 and 0.1 mM of DHPs. 
3.2. Analysis of the Molecular Interaction between HsrA and its DHP-Class Inhibitors   
In order to determine the affinity, the enthalpy and the stoichiometry of binding as well as to 
unravel the structural basis of the interaction between HsrA and its DHP-class inhibitors, ITC 
measurements and molecular docking analyses were carried out. As shown in Table 2, the ITC data 
provided dissociation constants in the micromolar range in all cases, while complexes of a 1:1 
stoichiometry were observed for all DHPs (Figure S1, Supplementary Materials), indicating that each 
HsrA monomer of the dimeric protein binds one molecule of DHP. Molecular docking suggested that 
DHP inhibitors bind to the native conformation of HsrA preferably at the C-terminal effector domain, 
interacting with amino acid residues directly involved in the structure of the helix-turn-helix (HTH) 
DNA binding motif, but also with other residues presumably essential for the domain stabilization 
(Table 2, Figure 2). 
Table 2. Analyses of interaction between HsrA and selected DHP drugs. 
DHP Drug ITC a Molecular Docking b 
 n 
Kd 
(µM) 
ΔH 
(kcal/mol) 
ΔG 
(kcal/mol) Interacting Residues 
Nifedipine 0.74 15 −5.0 −6.6 T206, R192, Y212, R208, K165 
Nicardipine 0.72 3.0 −2.0 −7.5 T153, E133, F149, R157, S68 
Nisoldipine 0.70 11 −2.2 −6.8 R157, T153, E133, P130, D131 
Nimodipine 0.71 4.1 −2.1 −7.3 P198, M195, I135, P148, K145, 
K194, V144 
Figure 1. In vitro inhibition of HsrA DNA binding activi selected DHP drugs. (a) Elect ophoretic
mobility shift assays (EMSAs) showing the ability of recombinant HsrA to specifically bind the promoter
region of target porGDAB operon. Increasing concentrations of HsrA (indicated in µM) were mixed
with 120 ng of target promoter and separated on a 6% PAGE. The Anabaena gene pkn22 was included as
non-specific competitor DNA in all assays. (b) DNA fragments were mixed with 6 µM of recombinant
HsrA protein in the presence of 2, 1, 0.5 and 0.1 mM of DHPs.
3.2. Analysis of the Molecular Interaction between HsrA and its DHP-Class Inhibitors
In order to determine the affinity, the enthalpy and the stoichiometry of binding as well as
to unravel the structural basis of the teraction b tween HsrA and its DHP-class inhibitors, ITC
measurements and molecular docking analyses were carried out. As shown in Table 2, the ITC
data provided dissociation constants in the micromolar range in all cases, while complexes of a 1:1
stoichiometry were observed for all DHPs (Figure S1, Supplementary Materials), indicating that each
HsrA monomer of the dimeric protein binds one molecule of DHP. Molecular docking suggested that
DHP inhibitors bind to the native conformation of HsrA preferably at the C-ter inal effector domain,
interacting with amino acid residues directly involved in the structure of the helix-turn-helix (HTH)
DNA binding motif, but also with other residues presumably essential for the domain stabilization
(Table 2, Figure 2).
Table 2. Analyses of interaction between HsrA and selected DHP drugs.
DHP Drug ITC a Molecular Docking b
n Kd (µM) ∆H (kcal/mol) ∆G (kcal/mol) Interacting Residues
Nifedipine 0.74 15 −5.0 −6.6 T206, R192, Y212, R208, K165
Nicardipine 0.72 3.0 −2.0 −7.5 T153, E133, F149, R157, S68
Nisoldipine 0.70 11 −2.2 −6.8 R157, T153, E133, P130, D131
Nimodipine 0.71 4.1 −2.1 −7.3 P198, M195, I135, P148, K145,K194, V144
Nitrendipine 0.75 9.0 −2.6 −6.9 P148, K147, Q190, V186, V183,V179, W173
Lercanidipine 0.81 20 −4.8 −6.4 P148, A187, Q190, V183, W173
a Absolute error in n is 0.06, relative error in Kd is 40%, absolute error in ∆H is 0.4 kcal/mol, and absolute error in
∆G is 0.2 kcal/mol. b Amino acid residues directly involved in forming the helix-turn-helix (HTH) DNA binding
motif of HsrA are highlighted in bold fonts.
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3.3. DHP-Class Inhibitors of HsrA Exhibit Strong Bactericidal Activities against H. pylori
DHP-class inhibitors of HsrA were evaluated for their antimicrobial properties against three
different strains of H. pylori, including two reference strains resistant to metronidazole (ATCC 43504),
and clarithromycin (ATCC 700684). As shown in Table 3, Nifedipine, Nicardipine, Nisoldipine,
Nimodipine, Nitrendipine and Lercanidipine showed potent bactericidal activities against H. pylori.
The minimal inhibitory concentration (MIC) values of all tested DHPs were in the range of 4 to 32 mg/L,
while most of these antihypertensive drugs exhibited minimal bactericidal concentration (MBC) values
against H. pylori ≤ 16 mg/L. Despite no relevant differences observed in the anti-H. pylori activities of
this set of DHP drugs according to their MIC or MBC values, Lercanidipine appeared slightly less
effective on the metronidazole-resistant strain.
Pharmaceutics 2019, 11, 681 10 of 18
Table 3. Minimal inhibitory and bactericidal concentrations of DHP-class inhibitors of HsrA against
different strains of H. pylori.
DHP Drug
MIC (MBC), mg/L
ATCC 700392 ATCC 43504 (MTZ-R) ATCC 700684 (CLR-R)
Nifedipine 8 (8) 16 (16) 8 (8)
Nicardipine 8 (8) 8 (8) 8 (8)
Nisoldipine 4 (4) 16 (16) 4 (4)
Nimodipine 8 (8) 16 (32) 4 (4)
Nitrendipine 8 (8) 16 (16) 8 (8)
Lercanidipine 8 (8) 32 (64) 8 (8)
Metronidazole 1 (2) 64 (128) 1 (2)
Clarithromycin ≤0.12 (≤0.12) ≤0.12 (≤0.12) 16 (32)
MTZ-R, metronidazole-resistant strain. CLR-R, clarithromycin-resistant strain. MBC, minimal bactericidal
concentration. MIC, minimal inhibitory concentration.
To further analyze the bactericidal effect of DHP drugs against H. pylori, time–kill kinetics were
carried out at 2 × the MIC values for the five selected most potent DHPs against the H. pylori strain
ATCC 700684. As depicted in Figure 3, no live bacteria could be detected at 24 h after exposition to
each DHP at these concentrations; however, significant differences were observed in the time–kill
kinetics caused by each drug. Notably, Nicardipine and Nisoldipine were completely lethal even
after only 4 h of exposition to these drugs. Nevertheless, no killing effect was perceived at this time
with the exposition to 2 × MIC of Nifedipine. In fact, the decline in bacterial counts due to the
exposition to Nifedipine was significantly slower (p < 0.05) compared to those produced by the rest of
bactericidal DHPs.
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Figure 3. Time–kill kinetics of DHP drugs against H. pylori strain ATC 70 684. Bacterial counts were
determined at time zero and after 4, 8, and 24 h of incubation with two times the MIC. Mixtures of
bacteria with DMSO (vehicle) instead of DHP were used as controls. Values are the averages of six
independent determinations; vertical bars represent standard deviations. Please note that in some
instances, the error bar is smaller than the symbols used.
Pharmaceutics 2019, 11, 681 11 of 18
3.4. Combinatory Effects of DHPs with Metronidazole and Clarithromycin against Antibiotic-Resistant H.
pylori Strains
The in vitro interactions between bactericidal DHPs and metronidazole or clarithromycin were
assessed by the checkerboard assay. In order to best appreciate the effect of each antimicrobial
combination on the improvement of the antibiotic efficacy, the tests were performed using the
corresponding antibiotic-resistant H. pylori strain, either the metronidazole-resistant strain ATCC 43504
(MIC = 64 mg/L) or the clarithromycin-resistant strain ATCC 700684 (MIC = 16 mg/L). As shown
in Table 4, DHPs exhibited only additive effect (slight synergy) or no interactions with the two
conventional antibiotics tested. However, in some cases, the increases observed in the activities of
the antibiotics in combination with certain DHPs were sufficient to change the classification of the
corresponding strain from resistant to susceptible, taking into account the breakpoints recommended
for each antibiotic [32]. Hence, Nimodipine reduced the MIC value of metronidazole up to 8 times
(FIC = 0.125) in the metronidazole-resistant strain ATCC 43504, while Lercanidipine reduced up to 16
times the MIC value of clarithromycin (FIC = 0.0625) in the clarithromycin-resistant strain ATCC 700684.
Table 4. Combinatory effect of DHPs with metronidazole and clarithromycin against two H.
pylori-resistant strains.
Strain Combination Tested FICantibiotic FICDHP FICI a Interaction b
ATCC 43504 (MTZ-R)
MTZ + Nifedipine 0.25 0.5 0.75 additive
MTZ + Nicardipine 1 1 2 no interaction
MTZ + Nisoldipine 0.5 0.5 1 additive
MTZ + Nimodipine 0.125 0.5 0.62 additive
MTZ + Nitrendipine 1 1 2 no interaction
MTZ + Lercanidipine 1 1 2 no interaction
ATCC 700684 (CLR-R)
CLR + Nifedipine 0.5 0.5 1 additive
CLR + Nicardipine 0.25 0.5 0.75 additive
CLR + Nisoldipine 0.5 0.5 1 additive
CLR + Nimodipine 0.5 0.5 1 additive
CLR + Nitrendipine 1 1 2 no interaction
CLR + Lercanidipine 0.0625 0.5 0.56 additive
a Fractional inhibitory concentration index (FICI) could be calculated as: FICA (MICA in the presence of B/MICA
alone) + FICB (MICB in the presence of A/MICB alone). b According to the FICI value, the interaction between
two compounds against a particular bacterial strain can be classified as: synergism (FICI ≤ 0.5), additive effect
(0.5 < FICI ≤ 1), no interaction or neutral (1 < FICI ≤ 4), or antagonism (FICI > 4).
3.5. Nimodipine and Nitrendipine Significantly Reduced the H. pylori Gastric Colonization in Mice
Since DHPs exhibited potent in vitro antimicrobial activities against H. pylori, their therapeutic
efficacies in vivo were determined in the mouse model of gastric colonization. Given the poor
bioavailability of DHPs due to their low solubility and substantial first-pass elimination [33], we
selected for the in vivo experiments, two DHPs that exhibit high oral LD50 values in mice—Nimodipine
and Nitrendipine (Table 1)—which allowed for treating the animals with higher therapeutic doses. Thus,
after four weeks of infection, mice were treated orally with 100 mg/kg/day of Nimodipine (9.4 times
lower than LD50) or Nitrendipine (25.4 times lower than LD50) in combination with omeprazole
for 7 days. Both antimicrobial therapies led to significant reduction in the H. pylori colonization of
mice stomachs compared to those observed in non-treated animals, as determined by two different
approaches (Figure 4).
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median (horizontal line) and the whiskers representing the minimum and maximum of all the data. * 
p < 0.05, ** p < 0.01 H. pylori-infected non-treated mice versus H. pylori-infected treated mice. 
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[19]. Beyond their efficacy in the control of hypertension and their demonstrated capacity to reduce 
cardiovascular morbidity and mortality, DHPs have shown strong antimicrobial activities against 
some bacterial and fungal pathogens such as Listeria monocytogenes [45], Mycobacterium tuberculosis [46], 
Staphylococcus aureus [47], Escherichia coli [48], Pseudomonas aeruginosa [49], Salmonella typhimurium [50], 
Figure 4. Antimicrobial effects of Nimodipine and Nitrendipine against H. pylori stomach colonization
in mice. (a) Bacterial counts from gastric biopsies are presented as CFU of H. pylori per mg of stomach.
(b) Quantitative PCR from gastric biopsies are presented as a ratio of bacteria per 10,000 murine
cells. Hp, H. pylori strain pre-mouse Sydney Strain 1 (PMSS1). Om, omeprazole. Hp + Om, infected
non-treated mice (n = 10), Hp + Nimodipine + Om (n = 9) and Hp + Nitendipine + Om (n = 9). Graphic
representations are box plots, with the box representing 50% of values around the median (horizontal
line) and the whiskers representing the minimum and maximum of all the data. * p < 0.05, ** p < 0.01 H.
pylori-infected non-treated mice versus H. pylori-infected treated mice.
4. Discussion
Developing a new chemical entity drug and delivering it to the market, known as de novo
drug discovery, is a time-consuming and expensive process with increasing regulatory requirements
and a high risk of failure—all of which could make the pharmaceutical industry a less desirable
choice for investors. Nowadays, drug repurposing has become a successful strategy to fast-track
therapeutic agents for the treatment of several emerging or rare diseases, such as AIDS, Alzheimer’s
disease and cancer [10,34–40], but also infections with multidrug-resistant strains of clinically relevant
pathogens [9,41–44].
Calcium channel blockers (CCBs) are small molecules that preferentially interact with L-type
voltage-operated calcium channels expressed in skeletal, smooth and cardiac muscles. These drugs
inhibit the influx of calcium into the sarcoplasm and thereby reduce contraction of arterial smooth
muscle and myocardium, leading to a decrement in blood pressure [18]. Among CCBs, DHPs are
the most frequently prescribed antihypertensive drugs worldwide given the strong antihypertensive
effects, safety, long-half-life and greater efficacy of some of these drugs and the minimization of side
effects (arterial hypotension, headache, flushing and ankle edema) with long-acting formulations [19].
Beyond their efficacy in the control of hypertension and their demonstrated capacity to reduce
cardiovascular morbidity and mortality, DHPs have shown strong antimicrobial activities against
some bacterial and fungal pathogens such as Listeria monocytogenes [45], Mycobacterium tuberculosis [46],
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Staphylococcus aureus [47], Escherichia coli [48], Pseudomonas aeruginosa [49], Salmonella typhimurium [50],
Aspergillus fumigatus and Candida albicans [51]. In addition, DHP drugs have shown antiprotozoal
activity against Leishmania spp. [52,53] and Trypanosoma cruzi [53,54].
H. pylori is the most prevalent human pathogen worldwide and a major cause of gastric and
duodenal ulcers and gastric cancer. The increasing resistance to first-line antibiotic drugs, especially
metronidazole and clarithromycin [55,56], has had a dramatic impact on the eradication rates, which
have fallen to 70% in the last few years [1]. In order to overcome the antimicrobial resistance strategies
evolved by this pathogen, novel molecular targets have emerged as candidates for therapeutic
interventions [23,24,57–61]. In a previous work, we validated a new effective anti-H. pylori therapeutic
target, the essential response regulator HsrA [17]. Several FDA-approved small-molecule drugs,
including natural flavonoids such as apigenin, chrysin, kaempferol and hesperetin, noticeably inhibited
the biological activity of HsrA and exhibited strong bactericidal activities against different strains of
H. pylori, including both metronidazole- and clarithromycin-resistant strains. In the present study,
we demonstrated that commercially available and highly prescribed DHP drugs such as Nifedipine,
Nicardipine, Nisoldipine, Nimodipine, Nitrendipine and Lercanidipine strongly inhibited the in vitro
biological activity of HsrA by interacting with this response regulator preferably by its C-terminal
effector domain, as previously observed with natural flavonoids [17]. Therefore, the inhibition of
HsrA activity by DHPs could be the result of direct blockage of key amino acid residues involved in
the structure of the HTH DNA binding motif and/or conformational changes in the effector domain
that destabilize the regulator interaction with its DNA target promoters. The molecular mechanisms
responsible for the previously documented antimicrobial activities of DHPs are poorly understood.
In M. tuberculosis, the antibacterial activity exhibited by DHPs has been related to calcium homeostasis
perturbation and loss of the Ca2+-dependent DNA gyrase activity [47,62]. Taking into account the
results presented here, the antimicrobial activity of DHPs goes beyond their function as calcium
channel blockers and additionally, these small-molecule drugs could act as potent inhibitors of essential
targets in the microbial cell. In fact, the antiprotozoal effect of DHPs on T. cruzi and Leishmania sp. has
been associated to respiratory chain inhibition [52,54], while no correlation was found between the
leishmanicidal activity and the Ca2+ channel blocking action of DHPs [52].
All the DHP-class inhibitors of HsrA studied in this work exhibited potent bactericidal activities
against different strains of H. pylori, including both metronidazole- and clarithromycin-resistant bacteria.
No relevant differences were observed in the antimicrobial potency of the six 1,4-DHP derivative
drugs according to their MIC or MBC values. However, the dynamics of the decline in the bacterial
counts at 2 × MIC appeared to be correlated with the lipophilicity of the drugs. Thus, Nicardipine
and Nisoldipine, which show higher log p values (lipophilicity parameter) [63], reduced significantly
faster the viability of H. pylori cells compared to Nifedipine. Correlation between DHP lipophilicity
and its antibacterial activity has been previously suggested [47]. Hence, lower lipophilicity of the
drug seems to result in poor translocation across the bacterial membrane and consequently lower
antimicrobial activity.
Despite some DHP drugs (e.g., amlodipine and lacidipine) having been previously found to
synergistically enhance the efficacy of conventional antibiotics [64,65], none of the six 1,4-DHP
derivatives studied here exhibited actual synergy in combination with metronidazole or clarithromycin.
However, some additive interactions noticeably reduced the MIC values of these antibiotics against
their respective H. pylori-resistant strains. Thus, as occurs with other non-antibiotics compounds such
as flavonoids, DHPs could reverse antibiotic resistance in certain H. pylori infections and enhance the
action of current antibiotic drugs in novel combinatory therapies.
In order to best simulate the human pathogenesis of H. pylori in the C57BL/6 mouse model,
we used the CagA+ mouse colonizing strain pre-mouse Sydney Strain 1 (PMSS1) for the in vivo
efficacy studies. The PMSS1 model persistently colonizes mice but also mimics the human host
response to CagA+ H. pylori infection, which results in more severe gastritis and a higher risk of gastric
adenocarcinoma than the infection with CagA− strains [20,66]. Oral treatments of PMSS1-infected mice
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with 100 mg/kg/day of marketed formulations of Nimodipine or Nitrendipine in combination with
omeprazole (140 mg/kg/day), daily for 7 days, significantly reduced the H. pylori gastric colonization
of the animal model according to two different methods of evaluation, bacterial counts and qPCR
analysis. The DHP oral dose applied to mice in this efficacy study (100 mg/kg/day) corresponds to a
human equivalent dose of 8 mg/kg/day [67], the recommended oral dose for Nimodipine (60 mg every
4 h) which could be prescribed to a young adult weighting 45 kg to prevent cerebral vasospasm after
aneurysmal subarachnoid hemorrhage [68]. However, the efficacy of these and other DHP derivative
drugs as anti-H. pylori antimicrobials could be presumably increased if drug bioavailability could be
improved, for example, through new formulations via nanotechnology [33] and/or rational chemical
modifications of the drug [69].
The DHP class of CCBs comprises several tens of low-molecular-weight compounds. Even a very
restricted and randomly selected set of six DHP derivatives studied in this work exhibited potent
bactericidal activities against antibiotic-resistant strains of H. pylori, and at least two of these drugs
significantly reduced the H. pylori stomach colonization in mice. Novel in vitro and in vivo analyses
must be carried out in order to identify the best choice of DHP-class anti-H. pylori drug, taking into
account several criteria including a high anti-H. pylori efficacy, low side effects in humans and a
desirable synergy with conventional antibiotics. Despite the fact that DHPs are well-tolerated drugs
with a low rate of adverse effects, especially the long-acting formulations [19], the prescription of these
anti-hypertensive drugs as antimicrobials should be taken into consideration in terms of their intrinsic
vasodilatation action and their potential hypotensive effect in both hypertensive and non-hypertensive
patients. Hence, DHPs as novel anti-H. pylori drugs could be used as part of personalized therapies
where the clinical characteristics of patients must be considered. On the other hand, the currently
prescribed DHP CCBs could be employed as “lead compounds” to synthesize more efficacious anti-H.
pylori drugs, even when the antihypertensive effects of these molecules are mitigated.
5. Conclusions
The results presented here support the use of DHP antihypertensive drugs in novel antimicrobial
strategies against H. pylori infections. Because of their high antimicrobial activities and their potential
to reverse antibiotic resistance in certain refractory infections, 1,4-DHP derivative drugs should be
included in both preclinical and clinical evaluations of novel and personalized combinatory therapies
against H. pylori. Further efforts to improve the bioavailability of these drugs as novel antimicrobials
must be conducted in order to increase efficacy, reduce doses and mitigate potential side effects.
6. Patents
The authors declare that a patent has been filed concerning the use of 4-phenyldihydropyridine
derivatives for the treatment and/or prevention of H. pylori infection.
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